KEY DETAILS
Counterfeit vials and unapproved retatrutide are spreading through India's weight-loss drug market, making it hard for buyers to confirm what they are actually injecting.
The FDA identified a possible link between GLP-1 drugs and vision loss in 2025, yet Ozempic and Mounjaro labels in the U.S. still carry no NAION warning.
Novo Nordisk is exploring whether a monthly dosing option could reignite growth for its GLP-1 franchise.
Roche released new obesity drug results as it works to establish itself alongside Eli Lilly and Novo Nordisk in the weight-loss market.
EASD 2026 in Milan will open with new retatrutide diabetes data, Mounjaro heart findings, and results from a Wegovy pill switching study.
In India, counterfeit vials of Mounjaro and unapproved batches of retatrutide are now moving through the same distribution channels as legitimate stock, leaving buyers unable to confirm what they are injecting. A separate safety question is unfolding in the U.S., where regulators flagged a possible vision risk tied to GLP-1 drugs months ago, yet no label has changed. Novo Nordisk and Roche are each making moves to shape where this class of drugs goes next, and a major European meeting next year will test some of the science.
The retatrutide found in India is not approved under any brand there, and it often circulates alongside real Mounjaro stock or is packaged to resemble it, so a buyer has no easy way to check the vial in front of them. Investigative reporting into the black market found unapproved manufacturing operations feeding the country's growing demand for weight-loss drugs, with counterfeit product moving through the same channels as legitimate imports. That mixing is what makes the market risky: even a careful buyer cannot tell a real dose from a fake one just by looking at it. If you or someone you know is considering a GLP-1 drug sourced outside a licensed pharmacy, I would suggest treating that uncertainty as a serious reason to pause.
That kind of uncertainty is not confined to unregulated markets, either. In the U.S., the FDA identified a possible link between GLP-1 drugs and NAION, a form of vision loss, back in 2025. Even so, the current labels for Ozempic and Mounjaro still carry no mention of that risk, which means patients relying on official prescribing information have no direct warning to consider. The gap between what regulators have flagged and what appears on the label is worth watching, especially for anyone already managing eye conditions alongside their treatment. Patients on either drug may want to raise the FDA's finding directly with their prescriber rather than assume the label reflects the latest safety signal.
Novo Nordisk, one of the two companies whose labels are under that safety scrutiny, is also working on the business side of its GLP-1 franchise. The company is exploring whether a monthly dosing option could reignite growth after a stretch of slower momentum for its weight-loss and diabetes drugs. A once-a-month version would set Novo apart from the weekly injections that currently define the category, and it could ease the burden on patients who find frequent dosing hard to sustain. Whether that translates into renewed growth depends on how the option performs in trials and how competitors respond.
One of those competitors is Roche, which released new obesity drug results as it works to establish itself alongside Eli Lilly and Novo Nordisk in the weight-loss market. Roche has been a later entrant than either of the two current market leaders, so fresh data matters for its case that it belongs in the same conversation. The company has not said its new results settle that question, and it will take more trial data before Roche's position in the market becomes clear. For now, the results add another data point to a market that is filling in with more competitors than it had even a year ago.
That competition, along with the open safety questions, will get a public airing at EASD 2026 in Milan, where new retatrutide diabetes data is expected to lead the agenda. Alongside it, researchers plan to present Mounjaro heart findings and results from a study on switching patients to a Wegovy pill. Retatrutide's presence at a major diabetes meeting is notable given how much of it is already circulating outside approved channels in places like India, and legitimate trial data may give doctors and patients a clearer basis for judging it. The Mounjaro heart findings and the Wegovy pill switching results will also matter for patients and clinicians deciding between injectable and oral options.
If there is one point that connects today's developments, it is that patients are being asked to do more of their own verification, whether that means confirming the source of a vial or asking directly about a safety signal that has not yet reached the label. I would suggest sticking with a licensed pharmacy and raising the FDA's vision loss finding with your prescriber before your next visit. Keeping an eye on the retatrutide and Mounjaro data expected out of EASD 2026 in Milan is also reasonable, since it may answer questions the market has been raising informally for months. Staying current on these details is a reasonable way to stay ahead of a market that is changing quickly.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.